Y-mAbs Therapeutics Inc (NASDAQ:YMAB)
| 4.41 BATS BZX Real-Time Price As of 10:17am ET |  -0.04 / -0.90%Today’s Change | 2.94 Today|||52-Week Range 20.48 | -9.73% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $193.9M |
Company Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Contact Information
Y-mAbs Therapeutics, Inc. 230 Park Avenue New York New York 10169-0005 |
Employees
Shareholders
| Mutual fund holders | 32.75% |
| Other institutional | 24.73% |
| Individual stakeholders | 22.11% |
Top Executives
| Thomas Gad | President, Chief Executive Officer & Director |
| Joris Wiel Jan Wilms | Chief Operating Officer & Senior Vice President |
| Bo Kruse | CFO, Secretary. Treasurer & Executive VP |
| Torben Lund-Hansen | Chief Technology Officer & Senior Vice President |
| Steen Lisby | Chief Scientific Officer & Senior Vice President |
